Ireland
--:--IST
Latest
Clinical Trials in Portugal / NCT06416644
Active, not recruiting Not applicable

The PORTuguese Registry of Supera Supported Femoral-Fopliteal Revascularization (SupPORT Registry)

NCT06416644 · tracked via the Priya Life Science Portugal tracker
Sponsor
Hospital do Divino Espírito Santo de Ponta Delgada
Phase
Not applicable
Started
2023-04-01
Last updated
2025-08-26

Condition(s) studied

Lower Limb IschemiaPeripheral Arterial DiseaseChronic Limb-Threatening IschemiaChronic Limb IschemiaAtherosclerosis of Femoral ArterySuperficial Femoral Artery StenosisSuperficial Femoral Artery OcclusionSuperficial Femoral Artery DiseaseSuperficial Femoral Artery LesionsPopliteal Artery OcclusionPopliteal Artery StenosisPopliteal Arterial Stenosis

Investigational drug(s) / intervention(s)

Supera Vasculomimetic Stent

Supera Vasculomimetic Stent: Femoral-popliteal revascularization with Supera Stent

Study summary

The SupPORT Registry aims at collecting real-world from Portuguese centers performing femoral-popliteal revascularization with Supera (r) implants. This is a prospective non-randomized non-controlled consecutive registry.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Evidence of symptomatic obstructive peripheral arterial disease. * All-comer patients undergoing endovascular lower-limb revascularization with Supera® stent implantation in the superficial femoral (SFA) or popliteal arteries. * Patient or legal representative understand the SupPORT registry procedures, and have voluntarily provided informed written consent regarding their participation. * Participant is willing to remain in the SupPORT Registry for at least 1 year. * Target lesion is a primary atherosclerotic lesion or a restenosis occurring in a non-stented of the SFA or the popliteal artery, distancing at least ≥ 1 cm from any previously implanted vascular stent. * Target lesion causes a ≥50% arterial obstruction (visually confirmed on digital subtraction angiography). Exclusion Criteria: * • Any contraindication for peri-interventional or post-interventional anti-thrombotic therapy (including, but not restricted to Non-fractioned heparina, low-molecular weight heparina \[LMWH\], Clopidogrel, Ticagrelol, Ticlopidine, Acetylsalicylic acid, dipiridamol, direct thrombin \[factor II\] or factor Xa inhibitors, vitamin-K antagonists). * Participation in other research study that may influence obtained results. * Pregnant or breastfeeding women, or expected pregnancy to occur during the study period. * Treatment of intrastent restenosis/occlusion of previous peripheral vascular stent. * Non-corrected hemodynamically significant obstructive arterial disease of the ipsilateral inflow arteries (aorta, iliac arteries)

Primary outcome measure(s)

Trial sites (15)

FacilityCityRegionStatus
Hospital de Faro - Centro Hospitalar do Algarve Faro Algarve
Hospital Divino Espírito Santo Ponta Delgada Azores
Hospital Garcia de Orta Almada Lisbon District
Centro Hospitalar Tâmega e Sousa Penafiel Porto District
Centro Hospitalar Vila Nova de Gaia e Espinho Vila Nova de Gaia Porto District
Hospital Santo Espírito Ilha Terceira Angra do Heroísmo Terceira
Centro Hospitalar Universitário de Coimbra Coimbra Portugal
Hospital da Senhora da Oliveira de Guimarães Guimarães Portugal
Hospital de Santa Marta - Centro Hospitalar Lisboa Central Lisbon Portugal
Hospital Egas Moniz - Centro Hospitalar Lisboa Central Lisbon Portugal
Hospital de Santa Maria - Centro Hospitalar Lisboa Norte Lisbon Portugal
Centro Hospitalar Universitário de Santo António Porto Portugal
Centro Hospitalar São João Porto Portugal
Centro Hospitalar de Trás-os-Montes e Alto Douro Vila Real Portugal
Centro Hospitalar Tondela Viseu Viseu Portugal

More Hospital do Divino Espírito Santo de Ponta Delgada trials in Portugal

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06416644 on ClinicalTrials.gov ↗ ← All trials in Portugal